Agenus Q3 2026 Results: Net Income $2.73M, Down 95.7% YoY
Agenus Inc. reported its financial results for the quarter ended September 30, 2026, highlighting continued investment in its clinical-stage immunotherapy pipeline and strategic collaborations. The filing reflects the company's focus on managing operational costs while advancing lead candidates toward key regulatory and clinical milestones.
- Key figure
- Net income $2.73M · -95.7% YoY